Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.
You may also be interested in...
GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.